Synthesis and anti-cancer activity evaluation of novel prenylated and geranylated chalcone natural products and their analogs

被引:77
作者
Wang, Hao-Meng [1 ]
Zhang, Li [1 ]
Liu, Jiang [1 ]
Yang, Zhao-Liang [1 ]
Zhao, Hong-Ye [1 ]
Yang, Yao [1 ]
Shen, Di [1 ]
Lu, Kui [1 ]
Fan, Zhen-Chuan [2 ,3 ]
Yao, Qing-Wei [4 ]
Zhang, Yong-Min [5 ]
Teng, Yu-Ou [1 ]
Peng, Yu [1 ]
机构
[1] Tianjin Univ Sci & Technol, Sino French Joint Lab Food Nutr Safety & Med Chem, Tianjin Key Lab Ind Microbiol, Key Lab Ind Fermentat Microbiol, Tianjin 300457, Peoples R China
[2] Tianjin Univ Sci & Technol, Key Lab Food Nutr & Safety, Minist Educ, Tianjin 300457, Peoples R China
[3] Obesita & Algaegen LLC, College Stn, TX 77845 USA
[4] Sphinx Sci Lab, Sycamore, IL 60178 USA
[5] Univ Paris 06, Inst Parisien Chim Mol, UMR CNRS 8232, F-75005 Paris, France
基金
中国国家自然科学基金; 对外科技合作项目(国际科技项目);
关键词
Prenyled chalcones; Geranylated chalcones; Antitumor agents; K562; cell; Apoptosis; ANGELICA-KEISKEI; ANTIBACTERIAL ACTIVITY; CHEMICAL-COMPONENTS; ISOBAVACHALCONE; XANTHOANGELOL; IODINATION;
D O I
10.1016/j.ejmech.2015.01.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Four natural chalcones bearing prenyl or geranyl groups, i.e., bavachalcone (la), xanthoangelol (lb), isobavachalcone (1c), and isoxanthoangelol (1d) were synthesized by using a regio-selective iodination and the Suzuki coupling reaction as key steps. The first total synthesis of isoxanthoangelol (1d) was achieved in 36% overall yield. A series of diprenylated and digeranylated chalcone analogs were also synthesized by alkylation, regio-selective iodination, aldol condensation, Suzuki coupling and [1,3]-sigmatropic rearrangement. The structures of the 11 new derivatives were confirmed by H-1 NMR, C-13 NMR and HRMS. The anticancer activity of these new chalcone derivatives against human tumor cell line K562 were evaluated by MTT assay in vitro. SAR studies suggested that the 5'-prenylation/geranylation of the chalcones significantly enhance their cytotoxic activity. Among them, Bavachalcone (1a) displayed the most potent cytotoxic activity against K562 with IC50 value of 2.7 mu M. The morphology changes and annexin-V/PI staining studies suggested that those chalcone derivatives inhibited the proliferation of K562 cells by inducing apoptosis. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:439 / 448
页数:10
相关论文
共 24 条
[1]   CHEMICAL-COMPONENTS OF ANGELICA-KEISKEI .7. CHALCONES FROM ANGELICA-KEISKEI [J].
BABA, K ;
NAKATA, K ;
TANIGUCHI, M ;
KIDO, T ;
KOZAWA, M .
PHYTOCHEMISTRY, 1990, 29 (12) :3907-3910
[2]  
BHALLA VK, 1968, TETRAHEDRON LETT, P2401
[3]   In vitro BACE-1 Inhibitory Phenolic Components from the Seeds of Psoralea corylifolia [J].
Choi, Yeon Hee ;
Yon, Gyu Hwan ;
Hong, Kyung Sik ;
Yoo, Dae Seok ;
Choi, Chun Whan ;
Park, Woo-Kyu ;
Kong, Jae Yang ;
Kim, Young Sup ;
Ryu, Shi Yong .
PLANTA MEDICA, 2008, 74 (11) :1405-1408
[4]   Cytotoxic effects of new geranyl chalcone derivatives isolated from the leaves of Artocarpus communis in SW 872 human liposarcoma cells [J].
Fang, Song-Chwan ;
Hsu, Chin-Lin ;
Yu, Yu-Shen ;
Yen, Gow-Chin .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2008, 56 (19) :8859-8868
[5]   Synthesis of Isobavachalcone and Some Organometallic Derivatives [J].
Grealis, John P. ;
Mueller-Bunz, Helge ;
Ortin, Yannick ;
Casey, Michael ;
McGlinchey, Michael J. .
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2013, 2013 (02) :332-347
[6]   Antioxidative components of Psoralea corylifolia (Leguminosae) [J].
Haraguchi, H ;
Inoue, J ;
Tamura, Y ;
Mizutani, K .
PHYTOTHERAPY RESEARCH, 2002, 16 (06) :539-544
[7]  
INAMORI Y, 1991, CHEM PHARM BULL, V39, P1604, DOI 10.1248/cpb.39.1604
[8]   New Synthetic Routes to Biologically Interesting Geranylated Flavanones and Geranylated Chalcones: First Total Synthesis of (±)-Prostratol F, Xanthoangelol, and (±)-Lespeol [J].
Jung, Doo Hwan ;
Lee, Yong Rok ;
Kim, Sung Hong .
HELVETICA CHIMICA ACTA, 2010, 93 (04) :635-647
[9]  
KHILEVICH A, 2010, Patent No. 2010009062
[10]   Isobavachalcone: An Overview [J].
Kuete, Victor ;
Sandjo, Louis P. .
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2012, 18 (07) :543-547